Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression

Park, Ha Young; Oh, In Jae; Kho, Bo Gun; Kim, Tae Ok; Shin, Hong Joon; Park, Cheol‐Kyu; Kwon, Yong Soo; Kim, Yu Il; Lim, Sung Chul; Kim, Young Chul; Choi, Yoo Duk

doi:10.4046/trd.2018.0070

Cited by 11 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The color of the chromogenic reaction is modified using a chromogen enhancement reagent; the specimen may then be counterstained and cover slipped. Results were interpreted using a light microscope [38]. All stained slides were evaluated by a board-certified pathologist for PD-L1 membrane staining.…”

Section: Methodsmentioning

confidence: 99%

Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation

Lee

Kim

Sung

et al. 2019

IJMS

View full text Add to dashboard Cite

Programmed cell death ligand 1 (PD-L1) expression is an important biomarker for predicting response to immunotherapy in clinical practice. Hence, identification and characterization of factors that predict high expression of PD-L1 in patients is critical. Various studies have reported the association of PD-L1 expression with driver genetic status in non-small cell cancer; however, the results have been conflicting and inconclusive. We analyzed the relationship between PD-L1 expression and clinicopathological factors including driver genetic alterations in 1000 resected lung cancers using a clinically validated PD-L1 immunohistochemical assay. PD-L1 expression was significantly higher in squamous cell carcinoma (SCC) compared to adenocarcinomas. PD-L1 expression in adenocarcinoma was associated with higher N-stage, solid histologic pattern, EGFR wild type, and ALK positive, but no significant association with the clinicopathological factors in SCC. EGFR mutant adenocarcinomas with distinctive clinicopathologic features, especially solid histologic pattern and higher stage showed higher PD-L1 expression. To the best of our knowledge, this study is the largest to evaluate the association between PD-L1 expression and clinicopathological and molecular features in lung cancer with a highly prevalent EGFR mutation. Therefore, our results are useful to guide the selection of lung cancer, even EGFR-mutated adenocarcinoma patients with PD-L1 expression, for further immunotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation

Lee

Kim

Sung

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…The U.S. FDA approved the 22C3 antibody for pembrolizumab, the 28-8 antibody for nivolumab, and SP142 for atezolizumab [46]. Many studies have reported that PD-L1/PD-1 levels correlate to treatment response and prognosis; however, further research will be needed to fully understand these pathways in cancer [47]. Calretinin, BAP1, podoplanin, CK5, CK5/6, and WT1 can be potentially used for the diagnosis of mesothelioma [48].…”

Section: Ihc Testsmentioning

confidence: 99%

Recent advances in diagnostic technologies in lung cancer

Park

Lee

Chang

2020

Korean J Intern Med

View full text Add to dashboard Cite

The increase in lung cancer incidence of Korea has been dampened since 2000; however, increased human lifespan, interest in health care and the widespread implementation of health examinations have resulted in a considerable rise in detection of small lesions that need to be differentiated from lung cancer. Detection of lung cancer at an early stage rather than at a symptomatic advanced stage is also increasing, suggesting that there are increasing diagnostic demands for small peripheral lung lesions. The development of new molecular diagnostics, including next generation sequencing, companion diagnostics that accompany development of new anti-cancer drugs, and re-biopsy for application of new therapeutic modality accelerate the development of lung cancer diagnostics. In this review, we extensively describe the current available diagnostic tools in lung cancer.

show abstract

“…Therefore, studies are ongoing to identify additional predictive tumor-based markers for ICI response, such as tumor-infiltrating lymphocytes, microsatellite instability (MSI), mismatchrepair deficiency, and tumor mutational burden (TMB) (10). However, PD-L1 expression on the tumor cell is the only biomarker for ICI response used in routine practice (11), and other potential candidates are not currently clinically relevant.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer

Park¹,

Oh²,

Kim³

et al. 2021

Transl Lung Cancer Res

Self Cite

View full text Add to dashboard Cite

Background: This study aimed to investigate the feasibility of using circulating tumor cells (CTCs), peripheral blood cells (PBCs), and circulating cell-free DNA (cfDNA) as biomarkers of immune checkpoint inhibitor treatment response in patients with advanced non-small cell lung cancer (NSCLC). Methods:We recruited patients diagnosed with advanced NSCLC who received pembrolizumab or atezolizumab between July 2019 and June 2020. Blood was collected before each treatment cycle (C1-C4) to calculate absolute neutrophil count (ANC), neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), and platelet-to-lymphocyte ratio (PLR). CTCs, isolated using the CD-PRIME TM system, exhibited EpCAM/ CK+/CD45− phenotype in BioViewCCBS TM . The cfDNA was extracted from plasma at the beginning of C1 and C4.Results: The durable clinical benefit (DCB) rate among 83 response-evaluable patients was 34%. CTC, PBC, and cfDNA levels at baseline (C1) were not significantly correlated with treatment response, although patients with DCB had lower CTC counts from C2 to C4. However, patients with low NLR, dNLR, PLR, and cfDNA levels at C1 had improved progression-free survival (PFS) and overall survival (OS). Patients with decreased CTC counts from C1 to C2 had higher median PFS (6.2 vs. 2.3 months; P=0.078) and OS (not reached vs. 6.8 months, P=0.021) than those with increased CTC counts. Low dNLR (≤2.0) at C1 and decreased CTC counts were independent factors for predicting survival.Conclusions: Comprehensive analysis of CTC, PBC, and cfDNA levels at baseline and during treatment demonstrated they might be biomarkers for predicting survival benefit. This finding could aid in risk stratification of patients with advanced NSCLC who are undergoing immune checkpoint inhibitor treatment.

show abstract

Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression

Cited by 11 publications

References 22 publications

Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation

Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation

Recent advances in diagnostic technologies in lung cancer

Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer

Contact Info

Product

Resources

About